LY2090314

Code: SML1438-25MG D2-231

Biochem/physiol Actions

LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) currently in clinical trials for cancer therapy. L...


read more

Your Price
€423.40 25MG
€520.78 inc. VAT
REQUEST

Biochem/physiol Actions

LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) currently in clinical trials for cancer therapy. LY2090314 has IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

LY2090314 can decrease the development of human MYCN amplified and non-amplified neuroblastoma (NB) cell lines in vitro. It has the ability to prevent the multiplication, colony formation and cell confluency of neuroblastoma.

Packaging

5, 25 mg in glass bottle

assay≥98% (HPLC)
coloryellow to orange
formpowder
Gene Informationhuman ... GSK3A(2931), GSK3B(2932)
InChI keyHRJWTAWVFDCTGO-UHFFFAOYSA-N
InChI1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)
Quality Level100
SMILES stringO=C(N1CCCCC1)N(C2)CCN3C4=C2C=C(F)C=C4C(C5=C(C6=CN=C7N6C=CC=C7)C(NC5=O)=O)=C3
solubilityDMSO: 10 mg/mL, clear
storage temp.−20°C
Cas Number603288-22-8
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN

GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.